List of EGFR inhibitors (anti-EGFR) - Drugs.com
monoclonal antibodies (eg, cetuximab, necitumumab): these bind to the extracellular component of the EGFR and prevent epidermal growth factor from binding to its own receptor, therefore preventing cell division. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-regulation, such as non-small-cell lung cancer ...
The Latest Battles Between EGFR Monoclonal Antibodies and …
2020年7月24日 · Four EGFR monoclonal antibody drugs (cetuximab, panitumumab, nimotuzumab, and necitumumab) are already on the market, and a dozen other EGFR monoclonal antibodies are in clinical trials. Here, we comprehensively review the newly identified biological properties and anti-tumor mechanisms of EGFR monoclonal antibodies.
Globally Approved EGFR Inhibitors: Insights into Their Syntheses ...
2021年11月4日 · Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been devoted to the discovery of new potent inhibitors.
Anti-EGFR Antibodies | Invitrogen - Thermo Fisher Scientific
Find the EGFR antibody that fits your needs. Choose from 1 of 280 EGFR antibodies, which have been validated in experiments with 626 publications and 906 images featured in our data gallery. Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications.
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and ...
2023年12月25日 · Two classes of EGFR-targeted cancer therapeutics include monoclonal antibodies (mAbs), which bind to the extracellular domain of EGFR, and tyrosine kinase inhibitors (TKIs), which mostly target the intracellular part of EGFR …
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms …
2020年6月23日 · Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time.
Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, …
2006年4月29日 · Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types. While both inhibit the EGFR pathway, they act via different mechanisms.
Molecular subtype-specific efficacy of anti-EGFR therapy in …
2021年7月12日 · Here we investigate the effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified by primary tumour location.
Structure-guided and phage-assisted evolution of a therapeutic anti ...
2022年7月30日 · Several introduced single mutations nearly abolished anti-EGFR antibody binding to EGFR—e.g., S492R, G465R, S464L or V441D mutation significantly reduced the cetuximab binding affinity, and...
Targeting of EGFR by a combination of antibodies mediates ...
2020年1月20日 · The dual epitope targeting anti-EGFR antibody combination Sym004, which has shown therapeutic efficacy in colorectal cancer and is currently being trialled in randomised studies, was used...